Osborne et al. reported that PAS-treated C57B/L Kras+/LSL-G12D; Trp53+/LSL-R172H; Pdx-Cre (KPC) mice survived longer, even compared with other mice of the same final tumour weight. This evidence concerns the gene KRAS and neoplasm.